Dorigo O, Oza AM, Pejovic T, Ghatage P, et al. Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial. Clin Cancer Res 2023 May 1:CCR-22-2595. doi: 10.1158/1078-0432.CCR-22-2595.
PMID: 37126016